Cynata Therapeutics logo

CYP - Cynata Therapeutics Share Price

A$1.09 0.0  0.9%

Last Trade - 4:15am

Sector
Healthcare
Size
Small Cap
Market Cap £56.7m
Enterprise Value £53.1m
Revenue £101k
Position in Universe 644th / 1836
Bullish
Bearish
Unlock CYP Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CYP Revenue Unlock CYP Revenue

Net Income

CYP Net Income Unlock CYP Revenue

Normalised EPS

CYP Normalised EPS Unlock CYP Revenue

PE Ratio Range

CYP PE Ratio Range Unlock CYP Revenue

Dividend Yield Range

CYP Dividend Yield Range Unlock CYP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CYP EPS Forecasts Unlock CYP Revenue
Profile Summary

Cynata Therapeutics Limited is a stem cell and regenerative medicine company. The Company is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, Cymerus. Its Cymerus technology facilitates manufacture of MSCs from a single donor and a single donation. The Company's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). The Company's technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Cymerus platform provides a source of MSCs that is independent of donor limitations and provides an off-the-shelf stem cell platform for therapeutic product use. The Company's MSCs produced using Cymerus technology, can be used to treat unrelated patients, without any need to match the recipient to the donor.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated March 12, 2003
Public Since December 20, 2007
No. of Shareholders: 2,670
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 101,885,053
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address L 3 62 Lygon Street, MELBOURNE, 3053, Australia
Web https://www.cynata.com/
Phone +61 3 98245254
Auditors Stantons International Audit and Consulting PTY Ltd
CYP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CYP
Upcoming Events for CYP
Similar to CYP
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.